alirocumab
regeneron,sanofi
['alirocumab', 'odyssey', 'cardio']
transiently achieved very low ldl-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the odyssey outcomes trial #ehj #acc23
Official Twitter account for the most successful family of CV journals. Articles FREE for 24h from time of tweet. @escardio #cardiotwitter